Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Dong-Jin HwangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-0055-1916
Chuanhe YangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38103, USA.
Yinan WangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38103, USA.
Hannah KelsoDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38103, USA.
Satyanarayana PochampallyDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Lawrence M PfefferDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38103, USA.ORCID 0000-0003-2809-1234
Duane D MillerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-6093-0985
Funding
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivityR01CA281977 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DUANE D MILLER, LAWRENCE MARC PFEFFER · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA281977NIH HHS 1R01CA281977-2the National Cancer Institute (NCI) to L.M.P. and D.D.M. CA-281977
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
anti-GBM activitybromodomainglioblastoma (GBM)PFI-3 analogstructure–activity relationship (SAR)temozolomide (TMZ)therapeutic enhancing drug (TED)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Structural Activity Relationship Analysis of New Diphenyl PFI-3 Analogues Targeting for the Treatment of Glioblastoma. · full record | OpenQuestion